A phase 1 trial of figitumumab combined with the EGFR/HER2/HER4 inhibitor dacomitinib revealed objective responses in advanced ACC, OC, and salivary gland cancer patients[188]. This evidence concerns the gene EGFR and adrenal cortex carcinoma.